Eventide Asset Management, LLC Kura Oncology, Inc. Transaction History

Eventide Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$10.71 - $18.33 $2.9 Million - $4.97 Million	-270,900 Reduced 13.14%	1,790,144 $32.8 Million
Q1 2022 May 16, 2022	BUY	$11.78 - $16.98 $8.25 Million - $11.9 Million	700,000 Added 51.43%	2,061,044 $33.1 Million
Q3 2021 Nov 15, 2021	BUY	$15.42 - $21.72 $10.1 Million - $14.3 Million	657,044 Added 93.33%	1,361,044 $25.5 Million
Q2 2021 Aug 16, 2021	SELL	$20.85 - $29.88 $19 Million - $27.3 Million	-913,573 Reduced 56.48%	704,000 $14.7 Million
Q1 2021 May 14, 2021	BUY	$24.75 - $39.14 $13.8 Million - $21.8 Million	557,573 Added 52.6%	1,617,573 $45.7 Million
Q4 2020 Feb 16, 2021	BUY	$29.0 - $41.62 $19.1 Million - $27.5 Million	660,000 Added 165.0%	1,060,000 $34.6 Million
Q3 2020 Nov 13, 2020	BUY	$16.3 - $30.64 $6.52 Million - $12.3 Million	400,000 New	400,000 $12.3 Million

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $603M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.